# Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

> **NCT02360475** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 507 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV vaccine GSK3003895A (formulation 1)
- **BIOLOGICAL:** RSV vaccine GSK3003898A (formulation 2)
- **BIOLOGICAL:** RSV vaccine GSK3003899A (formulation 3)
- **BIOLOGICAL:** Boostrix

## Key facts

- **NCT ID:** NCT02360475
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-20
- **Primary completion:** 2015-07-02
- **Final completion:** 2016-06-21
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360475, "Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02360475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*